EV/EBITDA spoločnosti ProMIS Neurosciences
Aká je hodnota metriky EV/EBITDA spoločnosti ProMIS Neurosciences?
Hodnota metriky EV/EBITDA spoločnosti ProMIS Neurosciences, Inc. je N/A
Aká je definícia metriky EV/EBITDA?
EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou ProMIS Neurosciences
Čomu sa venuje spoločnosť ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou ev/ebitda podobnou spoločnosti ProMIS Neurosciences
- Hodnota metriky EV/EBITDA spoločnosti Cashrewards je N/A
- Hodnota metriky EV/EBITDA spoločnosti Cosmo Lady (China) je N/A
- Hodnota metriky EV/EBITDA spoločnosti Moiselle International je N/A
- Hodnota metriky EV/EBITDA spoločnosti Atacama Copper je N/A
- Hodnota metriky EV/EBITDA spoločnosti Stellar AfricaGold je N/A
- Hodnota metriky EV/EBITDA spoločnosti XpresSpa Inc je N/A
- Hodnota metriky EV/EBITDA spoločnosti ProMIS Neurosciences je N/A
- Hodnota metriky EV/EBITDA spoločnosti Genetic Technologies je N/A
- Hodnota metriky EV/EBITDA spoločnosti Mammoth Services Inc je N/A
- Hodnota metriky EV/EBITDA spoločnosti Rua Life Sciences Plc je N/A
- Hodnota metriky EV/EBITDA spoločnosti Europlasma S.A je N/A
- Hodnota metriky EV/EBITDA spoločnosti Voleo Trading Systems Inc je N/A
- Hodnota metriky EV/EBITDA spoločnosti Tuktu Resources Ltd je N/A